

Health Technology Clinical Committee

Date: March 17, 2017

Time: 8:00 am – 1:30 pm

Location: SeaTac Conference Center, SeaTac, WA

Adopted: May 19, 2017

Meeting materials and transcript are available on the HTA website at:
www.hca.wa.gov/about-hca/health-technology-assessment/meetings-and-materials

HTCC Minutes

Members present: John Bramhall, MD, PhD; Gregory Brown, MD, PhD; Joann Elmore, MD, MPH; Chris Hearne, RN, DNP, MPH; Carson Odegard, DC, MPH; Christopher Standaert, MD; Kevin Walsh, MD; Tony Yen, MD

Clinical expert: Michael Chang, MD, PhD

HTCC Formal Action

- 1. Call to order:** Dr. Standaert, chair, called the meeting to order; members present constituted a quorum.
- 2. HTA program updates:** Josh Morse, program director, presented upcoming topics for committee meetings.
- 3. January 20, 2017 meeting minutes:** Draft minutes reviewed; no changes or updates suggested. Motion made to approve January 20, 2017 minutes as written, seconded. Committee voted to accept the minutes.
Action: Eight committee members approved the January 20, 2017 meeting minutes.
- 4. Pharmacogenomic testing – Draft findings and decision:** Chair referred members to the draft findings and decision and called for further discussion. Two comments were received on the draft decision. The committee reviewed and discussed the comments.
Action: Eight committee members voted to approve the pharmacogenomic testing findings.
- 5. Artificial discs - Draft findings and decision:** Chair referred members to the draft findings and decision and called for further discussion. Three comments were received on the draft decision. The committee reviewed and discussed the comments. One comment suggested a change to the last paragraph, first line. The committee reviewed and agreed with the suggested change, and, as amended it reads: "Patients must have advanced imaging ~~or~~ and clinical evidence of corresponding nerve root..."
Action: Eight committee members voted to approve the artificial disc findings and decision.

Final

6. Extracorporeal shock wave therapy (ESWT) for musculoskeletal conditions:

The chair introduced Michael Chang, MD, PhD, Physical Medicine Institute, Bellevue, WA.

Agency utilization and outcomes: Gary Franklin, MD, MPH, Medical Director for the Washington State Department of Labor and Industries, presented the state agency perspective for extracorporeal shock wave therapy for musculoskeletal conditions. The full presentation is published with the [March 17, meeting materials](#).

Scheduled and open public comments: The chair called for public comments. There were no comments.

Vendor report / HTCC question and answer:

Andrea Skelly, PhD, MPH, Spectrum Research, Inc., presented the evidence review of extracorporeal shock wave therapy for musculoskeletal conditions. The full presentation is published with the [March 17, meeting materials](#).

HTCC coverage vote and formal action:

Committee decision

Based on the deliberations of key health outcomes, the committee decided that it had the most complete information: a comprehensive and current evidence report, public comments, and state agency utilization information. The committee evaluated the available evidence. The committee discussed and voted on the evidence for use of extracorporeal shock wave therapy for musculoskeletal conditions compared to current alternative strategies. A majority of committee members found the technology unproven for safety, efficacy and cost-effectiveness based on the quality of available evidence. The committee considered and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable.

Based on these findings, the committee voted to not cover extracorporeal shock wave therapy for musculoskeletal conditions.

	Not covered	Covered under certain conditions	Covered unconditionally
Extracorporeal shock wave therapy for musculoskeletal conditions	8	0	0

Discussion

Limitations

Not applicable.

Action

The committee checked for availability of a Medicare national coverage decision (NCD). There is no NCD for Extracorporeal shock wave therapy for musculoskeletal conditions.

The committee reviewed and discussed clinical guidelines identified for extracorporeal shock wave therapy for musculoskeletal conditions from the following organizations:

- American Academy of Family Practice
- American College of Foot and Ankle Surgeons
- American College of Occupational and Environmental Medicine (ACOEM)
- Colorado Division of Workers Compensation
- Dutch Orthopedic Association

The committee chair directed HTA staff to prepare a findings and decision document for extracorporeal shock wave therapy for musculoskeletal conditions reflective of the majority vote for public comment, followed by consideration for final approval at the next public meeting.

7. The committee reviewed and discussed possible changes to the current HTCC bylaws. The group discussed different aspects of the bylaws. Josh Morse and Dr. Standaert, will craft a draft for the committee's consideration
8. Meeting adjourned.